NCT01163383 2025-07-25
131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol
Children's Hospital of Philadelphia
Available
Clinical Trials
9 trialsNCT01370330 2025-07-22
131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol
University of California, San Francisco
Available
NCT03649438 2024-12-11
131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma
University of Texas Southwestern Medical Center
No longer available
NCT03015844 2024-07-05
A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma
Northwell Health
Available
NCT01838187 2023-08-18
Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
Children's Hospital Medical Center, Cincinnati
No longer available
NCT01590680 2023-02-28
Expanded Access Protocol Using 131I-MIBG
Jubilant DraxImage Inc.
Available
NCT01377532 2020-05-06
Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma
University of California, San Francisco
Approved for marketing
NCT02961491 2019-01-30
Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
Molecular Insight Pharmaceuticals, Inc.
Approved for marketing
NCT00730444 2009-11-09
Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma
GE Healthcare
Approved for marketing